

Exhibit 269 [replacing Dkt. #1964-57] attached to Plaintiffs' Memorandum of Law in Support of Motion for Partial Summary Adjudication that Defendants did not Comply with Their Duties under the Federal Controlled Substances Act to Report Suspicious Opioid Orders and Not Ship Them (Second Corrected) at Dkt. #1910-1.

- Redactions withdrawn by Defendant

EXHIBIT 269

From: Cook, Sabrina [/O=MCKESSON/OU=NORTH AMERICA/CN=RECIPIENTS/CN=SABRINA COOK]
Sent: 11/1/2010 7:13:55 PM
To: Gustin, Dave [dave.gustin@mckesson.com]; Oriente, Michael [michael.oriente@mckesson.com]; Snider, Blaine [blaine.snider@mckesson.com]
CC: Wallis, Jeff [jeff.wallis@mckesson.com]
Subject: RE: Pain mgt

At the request of Greg, we increase the stores threshold by 10% on Thursday. Then on Friday they requested it to be changed to 12K, attached is the request. Friday order to be delivered today should have been okay. Let me know if there is anything you need me to do. Thanks.

Sabrina Cook
972-446-4563

From: Gustin, Dave
Sent: Monday, November 01, 2010 1:53 PM
To: Oriente, Michael; Snider, Blaine
Cc: Cook, Sabrina
Subject: RE: Pain mgt

Thx all. Sabrina?

Dave Gustin DRA North Central
937 840 8553

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Oriente, Michael
Sent: Monday, November 01, 2010 10:46 AM
To: Snider, Blaine; Gustin, Dave
Subject: RE: Pain mgt

Thanks Blaine. I will let Dave work with the account manager at Carrolton since this is a RNA.

Michael P. Oriente

Michael P. Oriente
Director Regulatory Affairs, NE Region
McKesson Pharmaceutical
400 Delran Parkway
Delran, N.J. 08075

Phone: 856-255-2184
Cell: 609-929-5880
Fax 856-764-9726

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized

review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Snider, Blaine
Sent: Monday, November 01, 2010 9:04 AM
To: Oriente, Michael; Gustin, Dave
Subject: FW: Pain mgt

Fyi.

Blaine Snider
Director of Operations
New Castle, Pa
724.924.9959
blaine.snider@mckesson.com

From: Wallis, Jeff
Sent: Monday, November 01, 2010 8:28 AM
To: Snider, Blaine
Subject: Fw: Pain mgt

Blaine,

Fyi...I will call Randy this am..

Jeff

From: Heiser, Randy <Randy.Heiser@giant eagle.com>
To: Wallis, Jeff
Sent: Mon Nov 01 04:49:30 2010
Subject: FW: Pain mgt

Jeff,

We are currently evaluating "pain mgt" as a corporate business opportunity

Looking at the Cleveland market place to begin (already in conversation with the Cleveland Clinic)

Please give me a call this week to discuss

From: 1605, Pharmacy Team Leader
Sent: Friday, October 29, 2010 9:32 AM
To: Carlson, Gregory
Cc: Chappell, Michael
Subject: MCKESSON THRESHOLD QUOT

Greg;

Just received our order from mckEss and we did NOT get the Endocet and Roxicet that we need desparately. We have increased our business and with a pain management specialist in town and several terminal patients we are seeing a rise

in these products. According to Mckesson we are limited to 9900 tablets and they recommend 12000 units. We need to get these medications or loose our customers. Can anything be done?

Thank you for your attention and assistance

Charlynn # 1605

From: Sharepoint [/O=MCKESSON/OU=NORTH AMERICA/CN=RECIPIENTS/CN=SHAREPOINT]
Sent: 10/29/2010 4:04:22 PM
To: Cook, Sabrina [sabrina.cook@mckesson.com]
CC: Gustin, Dave [dave.gustin@mckesson.com]; Pharma Reg Affairs RNA
Subject: Status of Threshold Change Request for GIANT EAGLE #1605

Hello,

Your Threshold Change Request for GIANT EAGLE #1605 titled "GIANT EAGLE #1605" that you submitted on 10/29/2010 11:56:13 AM has been *approved* by at the Giant Eagle DC on and by Dave Gustin, Director of Regulatory Affairs on 10/29/2010 11:56:14 AM

This request was for the following change(s):

Customer DEA#: BG7962295

Customer Number: 317631

Change Type: Permanent

Reason: Perm: Business growth (should be supported by corresponding sales increase)
increase in business and pain management specialist in aread as well as several termial ill patients.

9143 OXYCODONE Change to this number of doses 12000

DC Approval Comments:

DRA Approval Comments:

dgn

Thank you,

Dave Gustin

Director of Regulatory Affairs

Dave.Gustin@mckesson.com